GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>foreign surfaces of the tubing which deplete the AT3
That was what put the company on Atryn's trail over a decade
ago, ie our primeval target indication: management of heparin
resistance during extended CP bypass. The old annual reports
had a lot more technical detail than recent ones, very good
bedside reading matter.